NCT01802814 2024-02-09
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany
Phase 3 Completed
Clinical Trials
15 trialsNCT00113802 2021-08-19
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Gilead Sciences
Phase 2 Terminated
NCT00003337 2021-08-16
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 3 Unknown
NCT00003338 2021-08-16
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 2/3 Unknown
NCT00054834 2021-08-16
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 1 Terminated
NCT00421395 2021-08-16
Safety Study of NHL With 90Y-hLL2 IgG
Gilead Sciences
Phase 1/2 Completed
NCT00301821 2019-10-09
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00945815 2017-11-06
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00553501 2016-07-06
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01279707 2014-07-14
MARALL
Queen Mary University of London
Phase 1/2 Unknown
NCT00941928 2014-05-22
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00022685 2013-12-19
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00042913 2013-12-19
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00398372 2011-06-02
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Stanford University
Phase NA Completed
NCT00044902 2007-12-28
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
Amgen
Phase 2 Completed